Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed vs Immediate Hydroxyurea + ddI in Advanced HIV-1
NCT00008866Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of hydroxyurea in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Recovery of Total CD4+ T-Cell Counts at 48 weeks and Suppression of Plasma Viral Load at 48 weeks. Status: withdrawn.
02
Drugs
hydroxyurea
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00008866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008866.